<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136773</url>
  </required_header>
  <id_info>
    <org_study_id>CCIB002FUS12</org_study_id>
    <nct_id>NCT00136773</nct_id>
  </id_info>
  <brief_title>Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk
      factor for kidney disease. Aggressive blood pressure reduction is an important strategy to
      protect the kidney and reduce urinary protein which develops with kidney disease. This study
      will evaluate the effects of amlodipine/benazepril in reducing blood pressure and urinary
      protein in hypertensive subjects with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the urine albumin/creatinine ratio after 52 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who have progressed to diabetic kidney disease (urine albumin/creatinine ratio ≥ 300 µg/mg creatinine) after 52 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the ratio of urine albumin/creatinine ratio an estimate of kidney function after 52 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin resistance after 52 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine albumin secretion after 52 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in a marker of heart failure after 52 weeks</measure>
  </secondary_outcome>
  <enrollment type="Actual">332</enrollment>
  <condition>Albuminuria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine/benazepril</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate hypertension

          -  Type 2 diabetes mellitus

          -  Presence of protein in the urine (albuminuria)

        Exclusion Criteria:

          -  Kidney disease not caused by diabetes or hypertension

          -  Renal artery stenosis

          -  Myocardial infarction or stroke within the last 6 months

          -  Type 1 diabetes mellitus

          -  Pregnant or lactating females

          -  Cancer within the last 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2011</last_update_posted>
  <keyword>Albuminuria</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benazepril</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

